Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Hepatology

• Publication date

  2016-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/hep.28287PMID 26473614
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• International Association for the Study of Obesity

  2018cited by this paper
• Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms

  2015cited by this paper
• Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012.

  2014cited by this paper
• A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test. Diabetes Care 2001;24:539–548

  2014cited by this paper
• Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data

  2014cited by this paper
• Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

  2014cited by this paper
• Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

  2014cited by this paper
• Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease

  2013cited by this paper
• Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approaches

  2013cited by this paper
• Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.

  2013cited by this paper
• Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

  2012cited by this paper
• Differing Endoplasmic Reticulum Stress Response to Excess Lipogenesis versus Lipid Oversupply in Relation to Hepatic Steatosis and Insulin Resistance

  2012cited by this paper
• Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

  2012cited by this paper
• Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

  2012cited by this paper
• Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism

  2012cited by this paper
• Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research

  2012cited by this paper
• Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

  2011cited by this paper
• Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

  2011cited by this paper
• A novel surrogate index for hepatic insulin resistance

  2011cited by this paper
• Measuring and estimating insulin resistance in clinical and research settings.

  2010cited by this paper
• Dietary fructose exacerbates hepatocellular injury when incorporated into a methionine‐choline‐deficient diet

  2010cited by this paper
• Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?

  2010cited by this paper
• ORIGINAL ARTICLE: Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican‐American patients with Type 2 diabetes: a double tracer OGTT study

  2010cited by this paper
• Comparative Evaluation of Whole Body and Hepatic Insulin Resistance Using Indices from Oral Glucose Tolerance Test in Morbidly Obese Subjects with Nonalcoholic Fatty Liver Disease

  2010cited by this paper
• Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

  2009cited by this paper
• Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As

  2009cited by this paper
• Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

  2008cited by this paper
• High body mass index for age among US children and adolescents, 2003-2006.

  2008cited by this paper
• Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

  2008cited by this paper
• Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test

  2007cited by this paper
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

  2007cited by this paper
• Effect of Pioglitazone on the Metabolic and Hormonal Response to a Mixed Meal in Type II Diabetes

  2007cited by this paper
• Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test

  2007cited by this paper
• Inaugural Article: The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome

  2007cited by this paper
• Relationship between the hyperinsulinemic-euglycaemic clamp and a new simple index assessing insulin sensitivity in overweight and obese postmenopausal women.

  2007cited by this paper
• Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease

  2007cited by this paper
• The BIGTT Test

  2007cited by this paper
• The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease

  2006cited by this paper
• The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

  2006cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

  2005cited by this paper
• Epidemiology of Obesity

  2005cited by this paper
• Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity.

  2005cited by this paper
• Use and abuse of HOMA modeling.

  2004cited by this paper
• Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

  2002cited by this paper
• A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test

  2001cited by this paper
• Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.

  2000cited by this paper
• Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies.

  2000cited by this paper
• Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease

  1999cited by this paper
• Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

  1999cited by this paper
• A simple measure of insulin resistance.

  1995cited by this paper
• Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests. The Insulin Resistance Atherosclerosis Study.

  1995cited by this paper
• Simple measure of insulin resistance.

  1995cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans

  year unknowncited by this paper

• Molecular mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD): functional analysis of glucose and fructose metabolism pathways

  2025cites this paper
• A new perspective on non-invasive diagnosis of non- alcoholic fatty liver disease: evidence integration of inflammatory and metabolic biomarkers based on a scoping review

  2025cites this paper
• Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease

  2025cites this paper
• Effect of lipotoxic hepatocyte-derived extracellular vesicles in pancreas inflammation: essential role of macrophage TLR4 in beta cell functionality

  2025cites this paper
• Combination of non-alcoholic fatty liver disease and cholelithiasis: Pathophysiological and clinical relationships and specific features of therapy. A review

  2025cites this paper
• Sex differences in mortality and liver‐related events in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

  2024cites this paper
• Analytical and clinical comparison between two different analytical methods for the measurement of circulating insulin in patients with metabolic-dysfunction associated steatotic liver disease

  2024cites this paper
• Development of a novel diagnostic model to monitor the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma in females

  2024cites this paper
• Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants

  2024cites this paper
• Hepatic glucose metabolism in the steatotic liver

  2024cites this paper
• Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases

  2023cites this paper
• The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

  2023cites this paper
• Green Pea (Pisum sativum L.) Hull Polyphenol Extract Alleviates NAFLD through VB6/TLR4/NF-κB and PPAR Pathways.

  2023cites this paper
• Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk

  2023cites this paper
• Tetrastigma hemsleyanum leaf extracts ameliorate NAFLD in mice with low-grade colitis via the gut-liver axis.

  2023cites this paper
• Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease.

  2022cites this paper
• Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)

  2022cites this paper
• Gender Differences in Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Pathogenic aspects of the comorbid course of non-alcoholic fatty liver disease and cholelithiasis: a review and the authors’ results

  2022cites this paper
• Measuring and estimating insulin resistance in clinical and research settings

  2022cites this paper
• Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.

  2022cites this paper
• Incidence of Type 2 Diabetes in Children with Nonalcoholic Fatty Liver Disease.

  2022cites this paper
• The Microbiota and It’s Correlation With Metabolites in the Gut of Mice With Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction.

  2022cites this paper
• Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non‐alcoholic steatohepatitis

  2021cites this paper
• Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes.

  2021cites this paper
• Role of triglycerides to high-density lipoprotein cholesterol ratio in non-alcoholic fatty liver disease progression.

  2021cites this paper
• Гепатобилиарный континуум: неалкогольная жировая болезнь печени, желчнокаменная болезнь… Что еще?

  2021cites this paper
• Pathophysiological Communication between Hepatocytes and Non-Parenchymal Cells in Liver Injury from NAFLD to Liver Fibrosis.

  2021cites this paper
• Obesity and NAFLD: Same Problem?

  2020cites this paper
• The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients

  2020cites this paper
• Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD.

  2020cites this paper
• Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK

  2020cites this paper
• The metabolic basis of nonalcoholic steatohepatitis

  2020cites this paper
• Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research

  2020cites this paper
• Mechanisms for increased risk of diabetes in chronic liver diseases

  2020cites this paper
• FIB-4 index is a marker for a subsequent decrease in insulin secretion in a non-diabetic Japanese population

  2020cites this paper
• Non-Alcoholic Fatty Liver Disease: A 360-degree Overview

  2020cites this paper
• NAFLD and Insulin Resistance: A Multisystemic Disease

  2020cites this paper
• A Nomogram Model Based on Noninvasive Bioindicators to Predict 3-Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study

  2020cites this paper
• Peculiarities of insulin resistance syndrome in non-alcoholic steatogepatitis on the background of type 2 diabetes mellitus depending on the stage of diabetic kidney disease

  2020cites this paper
• La diète cétogène : bénéfique pour la stéatose hépatique non alcoolique ?

  2020cites this paper
• Normal-weight Obesity: A Hidden Pandemic

  2020cites this paper
• Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity

  2019influential citation
• Fatty liver, cardiometabolic disease and mortality.

  2019cites this paper
• Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease

  2019cites this paper
• New Aspects of Bilirubin Effects in Health and Disease: a Review

  2019cites this paper
• From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

  2019influential citation
• Клинико-патогенетические параллели неалкогольной жировой болезни печени и желчнокаменной болезни

  2019cites this paper
• Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: a cross-sectional study

  2019cites this paper
• Practical Predictors of Fibrosis in Non-alcoholic Fatty Liver Disease : Immunoglobulin-A and HOMA-IR

  2019cites this paper
• Validation of biochemical scores for liver steatosis before and 1 year after sleeve gastrectomy.

  2019cites this paper
• Examining the Frequency of Insulin Resistance in Children with Chronic Hepatic Disease

  2019cites this paper
• A systematic review on different models of inducing obesity in animals: Advantages and limitations

  2019cites this paper
• Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post‐load insulin resistance in nondiabetic patients with genotype 1

  2018cites this paper
• Metabolic dysfunction in a rat model of early‐life scarcity–adversity: Modulatory role of cafeteria diet

  2018influential citation
• Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance

  2018cites this paper
• Butyrate Protects Mice Against Methionine–Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels

  2018cites this paper
• Obesity and Nonalcoholic Fatty Liver Disease

  2018cites this paper
• Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease

  2017influential citation
• Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.

  2017cites this paper
• Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age‐dependent risk profiling study

  2017cites this paper
• The pharmacological management of NAFLD in children and adolescents

  2017cites this paper
• Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: new insights on a complex relationship

  2017cites this paper
• Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.

  2017cites this paper
• An extended fatty liver index to predict non-alcoholic fatty liver disease.

  2017cites this paper
• Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes.

  2017cites this paper
• Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease

  2016cites this paper
• The Impact of Segmental Anatomy on Hepatic Oncologic Resections

  2016cites this paper
• Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions

  2016cites this paper
• How to Diagnose Nonalcoholic Fatty Liver Disease

  2016cites this paper
• Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

  2016cites this paper
• Association between bilirubin and risk of Non-Alcoholic Fatty Liver Disease based on a prospective cohort study

  2016cites this paper
• Сочетание неалкогольной жировой болезни печени и желчнокаменной болезни: патофизиологические и клинические взаимосвязи, особенности терапии

  year unknowncites this paper